Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2025-04-17 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-04-17 English
POST-EFFECTIVE AMENDMENT NO 1 TO FORM F-1
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to Form F-1 Registration Statement filed with the SEC. It relates to the registration of securities for resale by a selling shareholder under the Securities Act of 1933. The document is a regulatory filing updating a prior registration statement and includes a preliminary prospectus for the resale of shares. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. This type of filing corresponds to a Capital/Financing Update (CAP) as it deals with securities registration and potential capital raising through share sales under a Standby Equity Purchase Agreement.
2025-04-11 English
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1
Capital/Financing Update Classification · 95% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1' and is filed with the SEC. It references registration statements on Form F-1, which is used for registration of securities by foreign private issuers under the Securities Act of 1933. The content discusses the registration of resale of ordinary shares and warrants by selling shareholders, including details about securities purchase agreements and resale prospectuses. This is a filing related to securities registration and capital raising activities, specifically a post-effective amendment to a registration statement. It is not a financial report, earnings release, or management discussion. It is clearly related to capital/financing updates and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities offering and registration, supporting a high confidence level.
2025-04-11 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release reporting year-end 2024 financial results and business updates, but the document itself is a filing to furnish that press release, not the full financial report. The document length is only 1683 characters, indicating it is a short filing. It states that the press release is furnished as Exhibit 99.1, which suggests this is a regulatory filing to provide information rather than the full annual or quarterly report. According to the rules, such filings that provide press releases or updates but are not full reports themselves should be classified as Regulatory Filings (RNS).
2025-04-07 English
ANNUAL REPORT
Annual Report FY 2024
2025-04-07 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It provides an update on a binding term sheet with a pharmaceutical company and includes forward-looking statements. The document does not contain detailed financial statements or comprehensive financial analysis, nor does it present a full annual or interim report. It is an ongoing update report typically filed by foreign private issuers to disclose material information between annual reports. Form 6-K filings are generally considered Regulatory Filings (RNS) as they serve as periodic updates and disclosures rather than full financial reports or other specific filings.
2025-03-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.